


CIRM 2.0

CALIFORNIA'S STEM CELL AGENCY



Translation Research Program: GWG Recommendations


Gil Sambrano

Director, Portfolio Development & Review
California Institute for Regenerative Medicine

CIRM 2.0 Translation Program

Objective: To support promising stem cell-based projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

CIRM 2.0: Translation Program



CIRM 2.0: Translation Program

Proof of concept with a candidate product

Therapeutic

Diagnostic

Device

Tool

30 months

24 months

24 months

24 months

\$4M/\$2M

\$1.2M

\$2M

\$1M

Key Points for GWG

All product types are assessed together.

- The review criteria are the same for all 4 product types.
- The goal is to identify the projects that are most likely to achieve the objective of this program.
- There is no need to reserve or balance award slots of any product type at this review.

Review Criteria

1. Did the project hold the necessary significance and potential for impact?
2. Was the rationale sound?
3. Was the project well planned and designed?
4. Was the project feasible?



RECOMMENDATIONS OF THE GWG FOR TRAN PROGRAM

Scoring System

- Score of “85-100”

Exceptional merit and warrants funding, if funds are available.

- Score of “1-84”

Not recommended for funding.

- Applications are scored by all scientific members of the GWG with no conflict.

TRAN: GWG Recommendations

	TRAN Apps	Funds
Exceptional merit and warrant funding, if funds available (Score 85-100)	4	\$16,563,513*
Not recommended for funding (Score 1-84)	13	

*Total budget amount approved by the ICOC for this cycle is **\$15M**.

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

GWG Vote on Review Process

1. *All members*: “The review was scientifically rigorous, there was sufficient time for all viewpoints to be heard, and the scores reflect the recommendation of the GWG.”
2. *ICOC patient advocate members*: “The review was carried out in a fair manner and was free from undue bias.”

All members voted unanimously in favor of 1 (20-0)

ICOC members voted unanimously in favor of 2 (6-0)